Elixir Life Holdings Limited 11277175 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is that of a holding company Digita Accounts Production Advanced 6.30.9574.0 true true false false 11277175 2022-04-01 2023-03-31 11277175 2023-03-31 11277175 bus:Consolidated 2023-03-31 11277175 core:CurrentFinancialInstruments 2023-03-31 11277175 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 11277175 bus:SmallEntities 2022-04-01 2023-03-31 11277175 bus:Audited 2022-04-01 2023-03-31 11277175 bus:FullAccounts 2022-04-01 2023-03-31 11277175 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 11277175 bus:RegisteredOffice 2022-04-01 2023-03-31 11277175 bus:Director5 2022-04-01 2023-03-31 11277175 bus:Director6 2022-04-01 2023-03-31 11277175 bus:Director7 2022-04-01 2023-03-31 11277175 bus:Director8 2022-04-01 2023-03-31 11277175 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 11277175 core:Subsidiary1 2022-04-01 2023-03-31 11277175 core:Subsidiary1 1 2022-04-01 2023-03-31 11277175 countries:EnglandWales 2022-04-01 2023-03-31 11277175 core:CostValuation 2022-03-31 11277175 2021-04-01 2022-03-31 11277175 2022-03-31 11277175 core:CurrentFinancialInstruments 2022-03-31 11277175 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 11277175 core:Subsidiary1 1 2021-04-01 2022-03-31 iso4217:GBP xbrli:pure

Registration number: 11277175

Prepared for the registrar

Elixir Life Holdings Limited

Annual Report and Financial Statements

for the Year Ended 31 March 2023

 

Elixir Life Holdings Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 6

 

Elixir Life Holdings Limited

Company Information

Directors

B L Wild

A K Shah

M Seekings

I A Gordon

Registered office

13 Roseberry Court
Stokesley
Middlesbrough
TS9 5QT

Auditors

Hazlewoods LLP
Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Elixir Life Holdings Limited

(Registration number: 11277175)
Balance Sheet as at 31 March 2023

Note

2023
£

Unaudited
2022
£

Fixed assets

 

Investments

4

100

100

Current assets

 

Debtors

5

206,001

-

Cash at bank and in hand

 

57,996

62,102

 

263,997

62,102

Creditors: Amounts falling due within one year

6

(521)

(4,105)

Net current assets

 

263,476

57,997

Net assets

 

263,576

58,097

Capital and reserves

 

Called up share capital

101

101

Profit and loss account

263,475

57,996

Shareholders' funds

 

263,576

58,097

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 7 March 2024 and signed on its behalf by:
 


A K Shah
Director


M Seekings
Director

 

Elixir Life Holdings Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
13 Roseberry Court
Stokesley
Middlesbrough
TS9 5QT
England

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Name of parent of group

These financial statements are consolidated in the financial statements of Riverdale Topco Limited.

The financial statements of Riverdale Topco Limited may be obtained from Companies House.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Judgements and estimation uncertainty

These financial statements do not contain any significant judgements or estimation uncertainty.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Elixir Life Holdings Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised


 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was as follows:

 

Elixir Life Holdings Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

 

4

Investments

2023
£

Unaudited
2022
£

Investments in subsidiaries

100

100

Subsidiaries

£

Cost

At 1 April 2022

100

Carrying amount

At 31 March 2022 and 31 March 2023

100

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

     

2023

2022

Subsidiary undertakings

Prettygate Dental Practice Limited

England and Wales

Ordinary

100%

100%

Subsidiary undertakings

Prettygate Dental Practice Limited

The principal activity of Prettygate Dental Practice Limited is the provision of dental services.

 

5

Debtors

2023
 £

Unaudited
2022
 £

Amounts owed by group undertakings

206,001

-

 

6

Creditors

2023
 £

Unaudited
2022
 £

Due within one year

Trade creditors

-

894

Other creditors

-

3,211

Corporation tax liability

521

-

521

4,105

 

Elixir Life Holdings Limited

Notes to the Financial Statements for the Year Ended 31 March 2023

 

7

Financial commitments, guarantees and contingencies

The company is bound by an intra-group cross guarantee in respect of borrowings held by Riverdale Bidco Limited. At the balance sheet date, the amounts guaranteed are £39,808,168 (2022 - £28,644,955).

 

8

Parent and ultimate parent undertaking

The company's immediate parent is Riverdale Tradeco Limited, incorporated in England and Wales. The ultimate parent is Riverdale Topco Limited, incorporated in England and Wales. The ultimate controlling party is Apposite Healthcare GP LLP, incorporated in England and Wales.

 

9

Disclosure under Section 444(5B) CA 2006

As permitted by Section 444 CA 2006, these accounts do not contain a copy of the company's Profit and Loss account or a copy of the Directors' Report. Accordingly, the Independent Auditors' Report has been omitted.

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 13 March 2024 was Martin Howard, who signed for and on behalf of Hazlewoods LLP.